Executive Decision: Francois Nader
In the "Executive Decision" segment, Cramer sat down with Dr. Francois Nader, president and CEO of orphan drug maker NPS Pharmaceuticals (NPSP - Get Report), a stock that's up 7.7% since Cramer first got behind the company in late October.
Nader commented on his company's newly announced deal securing the rights for its Gattex drug in Europe from partner Takeda Pharmaceutical Co. for $50 million. He said the all-stock deal is a win-win for both companies and returns Gattex to NPS, which has its sole focus on orphan drugs. While the drug currently only has 72 patients, Nader said he expects between 200 to 300 patients before year's end.
Nader also commented on the price of Gattex, which costs upwards of $200,000 per year. He said that ultimately Gattex saves the system money because patients' current treatments can last for 10 to 12 hours per day and cost between $200,000 and $600,000 per patient per year.In that context, Gattex offers real value, said Nader, not to mention the fact that patients can also lead productive lives instead of living at the hospital. When asked about health insurance reimbursements for such a costly drug, Nader said reimbursements have been favorable thus far. While market conditions are different in Europe, he is not expecting major issues going forward. Cramer said he continues to like the NPS Pharmaceutical story.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer said he found one silver lining to the moronic Cyprus bailout plan -- the end to the slump in gold that began last October. Cramer noted that the multi-year bull market in gold ended in October, when the SPDR Gold Shares (GLD), along with most of the major gold mining stocks, began to slump. But enter the Europeans to save the day by all but forcing wealthy investors to pull their money out of euros and put it into U.S. banks as well as in gold. Cramer said now is the time to get back into gold because in the months to come these wealthy European investors will be pushing gold higher. To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts